Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update
RS Wedemeyer, H Blume - Drug safety, 2014 - Springer
Proton pump inhibitors (PPIs) are used extensively for the treatment of gastric acid-related
disorders, often over the long term, which raises the potential for clinically significant drug …
disorders, often over the long term, which raises the potential for clinically significant drug …
Clinical significance of the cytochrome P450 2C19 genetic polymorphism
Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …
Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
CAM Stedman, ML Barclay - Alimentary pharmacology & …, 2000 - Wiley Online Library
Proton pump inhibitors have dramatically influenced the management of acid‐peptic
disorders in recent years. They all have a broadly similar mechanism of action and are …
disorders in recent years. They all have a broadly similar mechanism of action and are …
Pharmacokinetic drug interaction profiles of proton pump inhibitors
H Blume, F Donath, A Warnke, BS Schug - Drug safety, 2006 - Springer
Proton pump inhibitors are used extensively for the treatment of gastric acid-related
disorders because they produce a greater degree and longer duration of gastric acid …
disorders because they produce a greater degree and longer duration of gastric acid …
Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole
T Andersson - Clinical pharmacokinetics, 1996 - Springer
This review updates and evaluates the currently available information regarding the
pharmacokinetics, metabolism and interactions of the acid pump inhibitors omeprazole …
pharmacokinetics, metabolism and interactions of the acid pump inhibitors omeprazole …
Drug-drug interaction profiles of proton pump inhibitors
R Ogawa, H Echizen - Clinical pharmacokinetics, 2010 - Springer
Proton pump inhibitors (PPIs) are widely prescribed for the treatment of gastric acid-related
disorders and the eradication of Helicobacter pylori. In addition, they are routinely …
disorders and the eradication of Helicobacter pylori. In addition, they are routinely …
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development
SF Zhou, ZW Zhou, LP Yang… - Current medicinal …, 2009 - ingentaconnect.com
Cytochrome P450 2C9 (CYP2C9) is one of the most abundant CYP enzymes in the human
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state …
AL Frelinger, RD Lee, DJ Mulford, J Wu… - Journal of the American …, 2012 - jacc.org
Objectives: The aim of this study was to assess the effects of different proton pump inhibitors
(PPIs) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel …
(PPIs) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel …
[引用][C] Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human …
XQ Li, TB Andersson, M Ahlström, L Weidolf - Drug metabolism and …, 2004 - ASPET